Zosano Appoints New Chief Financial Officer

Seasoned financial and operational executive further strengthens management team

FREMONT, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation ZSAN ("Zosano" or the "Company"), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System ("ADAM™"), today announced the appointment of Greg Kitchener to the position of chief financial officer (CFO).

"We are pleased to announce the addition of Greg Kitchener to Zosano as our new CFO," said John Walker, chief executive officer and chairman of the board at Zosano. "Greg joins us at a pivotal time in the advancement of our clinical pipeline. Our lead program, M207, is moving towards an NDA filing with the FDA and we plan on adding additional assets to our portfolio over the next year."

"Greg has served in a variety of senior leadership roles at several publicly traded companies, during which he has supported growth, improved operations and built successful teams. We are confident that Greg will help Zosano accomplish our future goals and that his breadth of financial and operational experience will help transition the Company to its next phase as a commercial enterprise," concluded Mr. Walker.

Mr. Kitchener has over 20 years of broad financial leadership experience in financial planning and analysis, treasury, accounting and investor relations. Prior to joining Zosano, Mr. Kitchener served as CFO and executive vice president at BioPharmX Corporation BPMX. He was also previously a vice president of finance at Cepheid (acquired by Danaher Corporation) and a director of corporate planning at Synopsys, Inc. He received his undergraduate degree from the University of California, Santa Cruz and earned his MBA from Cornell University.

About M207
M207 is Zosano's proprietary formulation of zolmitriptan delivered utilizing its proprietary ADAM technology. Zosano's ADAM technology consists of titanium microprojections (microneedles) coated with drug, and in the case of M207, its formulation of zolmitriptan. The drug-coated microneedles penetrate into the epidermis and dermis, where the drug is dissolved and enters into the bloodstream. In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours. In November 2017, the Company announced the initiation of its long-term safety study evaluating M207 and expects to file a New Drug Application for M207 in the fourth quarter of 2019.

Forward-Looking Statements
This press release contains forward-looking statements regarding the timing of expected clinical development milestones and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
John Walker
Chief Executive Officer and Chairman of the Board
510-745-1200

Media Contact:
Sara Zelkovic
LifeSci Public Relations
sara@lifescipublicrelations.com
646-876-4933